pharma · Multiple System Atrophy · ATHE
ALTERITY THERAPEUTICS
ALTERITY THERAPEUTICS LTD
Alterity Therapeutics is a pharma organization headquartered in Melbourne, AU. It trades on NYSE under ticker ATHE. Primary therapeutic focus areas include Multiple System Atrophy. NovaPharmaNews links 3 clinical program
Melbourne, AU HQ
15 Employees
Public company Type
ATHE · NYSE Ticker
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Employees
- 15
- Programs
- 3
- Drugs
- 1
- Patents
- 4
ATH434 dose level 1
Phase 2 · small molecule · Multiple System Atrophy
ATH434 dose level 1 for Multiple System Atrophy is a Phase 2 program (small_molecule) at ALTERITY THERAPEUTICS LTD with 1 ClinicalTrials.gov record(s).
Internal code ATH434-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ALTERITY THERAPEUTICS LTD
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Multiple System Atrophy
- Status
- completed
- Trials
- 1